Table 6.
Inhibitory and chaperone activity of NOV (26) and NOEV (27). (a) Activity of 26 against wild-type and mutant human β-glucosidase. (b) Activity of 27 against wild-type and mutant human β-galactosidase.
| (a) | |||
|---|---|---|---|
| Compd | IC50 (µM) against wild type | Enhanced activity (fold) of mutant with 26 (30 µM) or 26 HCl (3 and 30 µM) | |
| 26 | 3 | F213I | 6 |
| 26 HCl | 0.502 | F213I, N188S, G202R, N370S | ∼2 |
| (b) | |||
|---|---|---|---|
| Compd | IC50 (µM) against wild type | Enhanced activity (fold) of mutants with 27 (0.2 µM) | |
| 27 | 0.2 | R201C | 5.1 |
| R201H | 4.5 | ||
| R457Q | 2.4 | ||
| W273L | 2.2 | ||
| Y83H | 2.0 | ||